ASX: CVB

19 November 2026

CurveBeam AI receives order for first four HiRise™ systems in China

Highlights

- The first order in China, for four HiRise™ weight-bearing CT (WBCT) systems, received from CurveBeam AI's China partner Weiying/Wego Orthopedics, following NMPA clearance.
- The order represents an important first step in the commercialisation of HiRise™ in China.
- The order progresses the Company's China commercialisation strategy under its long-term exclusive distribution agreement with Weiying.

Melbourne, Australia & Hatfield, Pennsylvania: CurveBeam AI Limited (ASX: CVB) **("CVB", "CurveBeam AI" or the "Company"),** a developer of point-of-care (PoC) specialised medical imaging (CT) equipment and AI enabled SaaS based clinical assessment solutions, is pleased to announce that it has received its first order for HiRise™ WBCT imaging systems for the Chinese market, with four systems ordered by its distribution partner Weiying/Wego Orthopedics.

The order represents an important step in the Company's strategy to establish HiRise™ as a leading WBCT imaging platform in China, providing orthopaedic clinicians with advanced three-dimensional imaging of the lower limb under natural bilateral weight bearing conditions.

The order follows the Company's long term exclusive distribution agreement with Weiying covering China, Hong Kong, Macau and Taiwan, announced on 30 October 2025. The agreement provides a framework for the commercialisation of HiRise™ in the region, with the potential for future product sales as market adoption develops.

The Company expects to receive the next milestone investment of A$1 million at an issue price of A$0.405 per share this quarter, following NMPA clearance of HiRise announced on 13 October 2026. This timing allows for international banking processes. While these can occasionally cause delays, receipt remains expected within the quarter.

Greg Brown, CEO of CurveBeam AI, said: "Receiving our first order for four HiRise™ systems in China is an important commercial step for CurveBeam. China represents a significant opportunity for our WBCT technology, and this order is an encouraging step in progressing our partnership with Weiying/Wego from agreement to commercial execution. We look forward to working with Weiying/Wego to support the introduction of HiRise™ into the Chinese market and to building further commercial momentum over time."

Release approved by the Board of Directors.

Telephone: +61 3 9620 0250
Email: info@curvebeamai.com
Website: curvebeamai.com

Corporate Office
Level 10, 10 Queen Street
Melbourne, Victoria, 3000, Australia

Global Operations Headquarters
2800 Bronze Dr., Suite 110
Hatfield, PA 19440 USA

About CurveBeam AI Limited

CurveBeam AI Limited (ASX: CVB) develops, manufactures and sells specialised medical imaging ("**CT**") scanners, coupled with AI SaaS-based clinical assessment solutions, to support medical practitioners in the management of musculoskeletal conditions. The Company's flagship CT scanner, HiRise™, performs weight bearing CT scans as well as traditional non weight bearing CT scans, providing a range of advantages over the use of traditional CT or MRI devices. CurveBeam AI has more than 70 employees with its corporate office, AI and IP functions located in Melbourne, VIC, Australia and global operations headquarters in Hatfield, Pennsylvania, USA.

For further information go to https://curvebeamai.com

Forward-Looking Statements

This announcement contains certain forward-looking statements, including statements of intent, belief or current expectations with respect to the Company's business and operations, market conditions, results of operations and financial condition. Forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors which may cause actual results, performance or achievements to differ materially from those expressed or implied in such statements.

Readers are cautioned not to place undue reliance on these forward-looking statements. Except as required by law, CVB undertakes no obligation to update or revise any forward-looking statements to reflect any change in expectations or events, conditions or circumstances on which such statements are based.

Investor / media enquiries

Matthew Wright
NWR Communications
+61 (0) 451 896 420
matt@nwrcommunications.com.au